HylX platform: Precision-Engineered HA Platforms for Targeted Therapeutics

The HylX represents proprietary hyaluronan-based delivery platforms designed to delivery hyaluronan-drug conjugates to where require targeted delivery and localized tissue exposure.

• CD44-mediated, targeted delivery
• Tunable polymer design for payload versatility:
• Enhanced local retention, reduced systemic burden
• Validated BBB, BRB, Stroma, penetration
• HA conjugation unlocks hidden or enhanced mechanisms of action
• Unique mucosal healing and anti-inflammatory dual activity

Preclinical and clinical-stage HylX platform application assets applications are illustrated as below:

• HylNeuro™ – CNS-targeted delivery across BBB for neurodegenerative diseases
• HylTargis™ – CD44 solid tumor selective delivery
• HylMusa™ – Gastrointestinal selective delivery for mucosal healing
• HylRetinX™ – Oral and topical delivery across BRB for retinal diseases
• HylCaryo™ –HA nanoparticle system for RNA/nucleic acid delivery